Get started
Author

Rita M. Cool

Observed names: R. Cool, R. M. Cool, R.M. Cool, Rita Cool, Rita M Cool
OpenAlex ID: A5049299676
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
2020 · Pamela Sue Becker, Elizabeth A. Griffiths, et al. · Journal of the National Comprehensive Cancer Network · 131
PDF
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
2022 · Elizabeth A. Griffiths, Vivek Roy, et al. · Journal of the National Comprehensive Cancer Network · 83
PDF
Recurrent Peripheral Arterial Thrombosis Induced by Cisplatin and Etoposide
2002 · Rita M. Cool, Jon D. Herrington, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 49
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
2021 · Elizabeth A. Griffiths, Laura M. Alwan, et al. · Journal of the National Comprehensive Cancer Network · 48
West Nile Encephalitis in 2 Hematopoietic Stem Cell Transplant Recipients: Case Series and Literature Review
2003 · D. S. Hong, K. L. Jacobson, et al. · Clinical Infectious Diseases · 44
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
2022 · Borje S. Andersson, Peter F. Thall, et al. · Bone Marrow Transplantation · 10
PDF
Thalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma
2002 · Rita M. Cool, Jon D. Herrington · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 6
The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
2013 · Kaci Wilhelm, Roy Chemaly, et al. · Journal of Oncology Pharmacy Practice · 4
Rhabdomyolysis after Concomitant Use of Simvastatin and Voriconazole in an Allogeneic Stem Cell Transplant Patient
2013 · Rita M Cool, Alison M Gulbis · Journal of Pharmacy Technology · 3
A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation
2010 · Marina Konopleva, Zeng Zhihong, et al. · Blood · 3
Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse
2012 · Christopher B. Benton, Marina Konopleva, et al. · Blood · 1
Elevated plasma levels of tacrolimus after concurrent use of tacrolimus and voriconazole in the bone marrow transplant setting
2004 · R.M. Cool, C. Ippoliti, et al. · Transplantation and Cellular Therapy · 1
PDF
Safety and Efficacy of a New High-Dose Chemotherapy (HDC) Regimen of Panobinostat (Pano), Gemcitabine (Gem), Busulfan (Bu) and Melphalan (Mel) (Pano/GBM) with Autologous Stem Cell Transplant (ASCT) for Patients (pts) with High-Risk (HR) or Refractory/Relapsed (R/R) Myeloma (MM) – Matched Pair Comparisons with a Concurrent Control Cohort
2023 · Yago Nieto, Zixi Yang, et al. · Transplantation and Cellular Therapy
Safety and Efficacy of a New High-Dose Chemotherapy Regimen of Panobinostat, Gemcitabine, Busulfan and Melphalan for 1st or 2nd Salvage Autologous Stem Cell Transplant for Patients with Refractory/Relapsed or High-Risk Myeloma: Matched Pair Comparisons with Concurrent Control Cohorts
2023 · Yago Nieto, Zixi Yang, et al. · SSRN Electronic Journal
The Impact of Pre-Transplant Valganciclovir on Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplant
2012 · K. Wilhelm, A. Gulbis, et al. · Transplantation and Cellular Therapy
Use of Palifermin in Allogeneic Stem Cell Transplantation (SCT) for Patients with Acute Lymphoblastic Leukemia (ALL)
2009 · J.E. Anderson, A.M. Gulbis, et al. · Transplantation and Cellular Therapy
Works count: 16
Citation count: 383
H-index: 6
I10-index: 6
Year
Topic
Type